AWMF: Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 6.0, 2021, AWMF Registernummer: 043/022OL., 2021. www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
Bazinet, A., Zorn, K. C., Taussky, D. et al.: Favorable preservation of erectile function after prostate brachytherapy for localized prostate cancer. Brachytherapy, 2019. http://www.ncbi.nlm.nih.gov/pubmed/31837989
Blanchard, P., Davis, J. W., Frank, S. J. et al.: Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int, 121: 540, 2018. http://www.ncbi.nlm.nih.gov/pubmed/28941030
Cox, J. D., Stetz, J., Pajak, T. F.: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 31: 1341, 1995. https://www.ncbi.nlm.nih.gov/pubmed/7713792
Cozzi, G., Musi, G., Bianchi, R. et al.: Meta-analysis of studies comparing oncologic outcomes of radical prostatectomy and brachytherapy for localized prostate cancer. Ther Adv Urol, 9: 241, 2017. http://www.ncbi.nlm.nih.gov/pubmed/29662542
Davis, B. J., Horwitz, E. M., Lee, W. R. et al.: American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy, 11: 6, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22265434
Fisher, C. M., Troncoso, P., Swanson, D. A. et al.: Knife or needles? A cohort analysis of outcomes after radical prostatectomy or brachytherapy for men with low- or intermediate-risk adenocarcinoma of the prostate. Brachytherapy, 11: 429, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22727472
Giberti, C., Chiono, L., Gallo, F. et al.: Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol, 27: 607, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19455340
Goy, B. W., Burchette, R., Soper, M. S. et al.: Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer. Urology, 136: 180, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31704459
Grimm, P., Billiet, I., Bostwick, D. et al.: Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int, 109 Suppl 1: 22, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22239226
Hoffman, K. E., Penson, D. F., Zhao, Z. et al.: Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA, 323: 149, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31935027
Hoskin, P. J., Colombo, A., Henry, A. et al.: GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol, 107: 325, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23773409
Hunter, G. K., Reddy, C. A., Klein, E. A. et al.: Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer. Prostate Cancer, 2012: 853487, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22577562
Kalapara, A. A., Verbeek, J. F. M., Nieboer, D. et al.: Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative. Eur Urol Oncol, 3: 80, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31564531
Miwa, S., Mizokami, A., Konaka, H. et al.: Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer. Prostate Int, 1: 117, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24223413
Ohashi, T., Yorozu, A., Saito, S. et al.: Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study. Int J Radiat Oncol Biol Phys, 93: 141, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26279031
Onishi, K., Tanaka, N., Miyake, M. et al.: Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer. Clin Transl Radiat Oncol, 14: 51, 2019. http://www.ncbi.nlm.nih.gov/pubmed/30547097
Pardo, Y., Guedea, F., Aguilo, F. et al.: Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol, 28: 4687, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20921463
Peinemann, F., Grouven, U., Bartel, C. et al.: Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol, 60: 881, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21763066
Salembier, C., Lavagnini, P., Nickers, P. et al.: Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol, 83: 3, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17321620
Schouten, B. W., Bohnen, A. M., Groeneveld, F. P. et al.: Erectile dysfunction in the community: trends over time in incidence, prevalence, GP consultation and medication use–the Krimpen study: trends in ED. J Sex Med, 7: 2547, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20497307
Smith, D. P., King, M. T., Egger, S. et al.: Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ, 339: b4817, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19945997
Stock, R. G., Kao, J., Stone, N. N.: Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol, 165: 436, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11176391
Stone, N. N., Stock, R. G.: Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. Brachytherapy, 2: 32, 2003. http://www.ncbi.nlm.nih.gov/pubmed/15062161
Sureda, A., Fumado, L., Ferrer, M. et al.: Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study. Health Qual Life Outcomes, 17: 11, 2019. http://www.ncbi.nlm.nih.gov/pubmed/30642340
Tanaka, N., Asakawa, I., Hasegawa, M. et al.: Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan. Int J Urol, 27: 17, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31549770
Tom, M. C., Reddy, C. A., Smile, T. D. et al.: Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy. Brachytherapy, 19: 43, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31813740
Viktorin-Baier, P., Putora, P. M., Schmid, H. P. et al.: Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. BJU Int, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31965694
Vuolukka, K., Auvinen, P., Palmgren, J. E. et al.: Long-term efficacy and urological toxicity of low-dose-rate brachytherapy (LDR-BT) as monotherapy in localized prostate cancer. Brachytherapy, 18: 583, 2019. http://www.ncbi.nlm.nih.gov/pubmed/31227400
Winoker, J. S., Say, R. K., Mehrazin, R. et al.: Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms. Brachytherapy, 18: 332, 2019. http://www.ncbi.nlm.nih.gov/pubmed/30890317
Yamada, Y., Rogers, L., Demanes, D. J. et al.: American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy, 11: 20, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22265435
Zhou, Z., Yan, W., Zhou, Y. et al.: (125)I low-dose-rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer. Oncol Lett, 18: 72, 2019. http://www.ncbi.nlm.nih.gov/pubmed/31289474
